Business
Voyageur Pharmaceuticals Ltd. Announces First Closing of Private Placement
(TheNewswire) News Release – Calgary, Alberta – TheNewswire - Decem...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces First Closing of Private Placement \n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n News Release – Calgary, Alberta –\n \n \n TheNewswire -\n \n \n December 23, 2022\n \n \n :\n \n \n Voyageur Pharmaceuticals Ltd. (TSX.V:\nVM) (USA: VYYRF) (the \"\n \n \n Company\n \n \n \" or \"\n \n \n Voyageur\n \n \n \") is\npleased to announce that, further to its news release dated December\n6, 2022, it has completed the first closing of its non-brokered\nprivate placement of up to units of the Company (\"\n \n \n Units\n \n \n \") for\nproceeds of up to CDN$650,000, with each Unit being sold at a price of\n$0.07 per Unit (the \"\n \n \n Offering\n \n \n \").  Under the first closing of\nthe Offering, the Company issued 2,571,369 Units for aggregate gross\nproceeds of $179,995.93. Each Unit is comprised of one (1) common\nshare (\"\n \n \n Common\nShare\n \n \n \") and one (1) Common Share purchase\nwarrant (\"\n \n \n Warrant\n \n \n \") of Voyageur. Each Warrant\nentitles the holder thereof to purchase one Common Share for $0.12\nexpiring twenty-four (24) months from the date of issuance.\n \n \n \n \n Pursuant to the first closing of the Offering, Voyageur\npaid a cash commission to a qualified non-related party in the amount\nof $2,800 and issued 40,000 broker warrants entitling the holder to\nacquire one Common Share at a price of $0.07 per share for a period of\none (1) year from the date of issuance.\n \n \n \n The gross proceeds received by Voyageur from the Offering will be used\nto advance Voyageur’s project in the following order:\n \n \n \n \n \n Commissions & Offering Costs\n \n \n \n \n $35,000\n \n \n \n \n \n \n SmoothX & Corporate Marketing\n \n \n \n \n $175,000\n \n \n \n \n \n \n FDA EMA Testing\n \n \n \n \n $180,000\n \n \n \n \n \n \n Legal\n \n \n \n \n $50,000\n \n \n \n \n \n \n Auditing\n \n F\n \n ees\n \n \n \n \n $60,000\n \n \n \n \n \n \n Corporate G&A\n \n \n \n \n $150,000\n \n \n \n \n \n \n Total\n \n \n \n \n $650,000\n \n \n \n \n \n \n Completion of the Offering is subject to regulatory\napproval including, but not limited to, the approval of the TSX\nVenture Exchange. The Common Shares, Warrants and broker warrants\nissued will be subject to a four-month hold period from the date...